Advanced and recurrent gynecological cancers are associated with poor prognosis and lack
of effective treatment. The developments of the molecular mechanisms on cancer …

Gynecological cancers are known for being very aggressive at their advanced stages.
Indeed, the survival rate of both ovarian and endometrial cancers is very low when …

Endometrial cancer comprises a heterogeneous group of tumors, with distinct risk factors,
clinical presentation, histopathological features and molecular characteristics. Currently …

The epidermal growth factor receptor (EGFR) is one of the most well-studied signaling
pathways in cancer progression. As a result, numerous therapeutics including small …

Background The aim of this study was to summarize the global predicting role of hormone
receptors for survival in endometrial cancer. Methods Eligible studies were identified and …

Purpose Reactive oxygen species (ROS) are oxygen-containing molecules that have high
reactivity and play roles in protection or harm the cancer cells. We aimed to clarify the …

Level I evidence exists for use of adjuvant chemotherapy in stage IIIC endometrial cancer
(positive lymph nodes), although results of randomized trials have varied. Chemotherapy is …

Simple Summary HER2 testing in endometrial cancer (EC) has gained renewed interest as
a therapeutic target. However, HER2 status has not been investigated in the context of the …

Most sporadic endometrial cancers (ECs) can be histologically classified as endometrioid,
serous, or clear cell. Each histotype has a distinct natural history, clinical behavior, and …

PURPOSE The TAPUR Study is a pragmatic basket trial evaluating antitumor activity of
commercially available targeted agents in patients with advanced cancers harboring …